Xarelto Falters Again In ACS Bid, As Competitors Aim To Catch Up To J&J Drug’s Label

FDA’s third rejection of J&J’s attempt to expand use of Xarelto to ACS patients comes as competing oral anticoagulants await agency action on pending applications that could match Xarelto’s breadth of approved indications.